Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Fornaro, Michele ^a,b   De Berardis, Domenico ^c   Perna, Giampaolo ^d,e,f   Solmi, Marco ^g,h   Veronese, Nicola ^g,h   Orsolini, Laura ⁱ   Buonaguro, Elisabetta Filomena ^b   Iasevoli, Felice ^a   Köhler, Cristiano André ^j   Carvalho, André Ferrer ^j   De Bartolomeis, Andrea ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c G Mazzini Hospital   (Italy)

^d Department of Clinical Neurosciences   (Italy)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PADOVA   (Italy)

^h Institute of Clinical Research and Education in Medicine (IREM)   (Italy)

ⁱ UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^j FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LURASIDONE;

AKATHISIA; BIPOLAR DEPRESSION; CLINICAL OUTCOME; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; HUMAN; MONOTHERAPY; NAUSEA; PSYCHOPHARMACOTHERAPY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STUDY DESIGN; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); BIPOLAR DISORDER; DRUG APPROVAL; PATHOLOGY;

BIPOLAR DISORDER; DRUG APPROVAL; HUMANS; LURASIDONE HYDROCHLORIDE;

EID: 85019547479     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/3084859     Document Type: Review

References (107)

1. APA, Diagnostic and Statistical Manual for Mental Disorders, APA, Washington, DC, USA, 4th edition, 1994.
2. American Psychiatric Association, "Bipolar and related disorders, " in Diagnostic and StatisticalManual forMental Disorders, p. 123, American Psychiatric Association, Washington, DC, USA, 2013.
3. H. A. Swartz and M. E. Thase, "Pharmacotherapy for the treatment of acute bipolar II depression: current evidence, " The Journal of Clinical Psychiatry, vol. 72, no. 3, pp. 356-366, 2011.
4. K. N. Fountoulakis, Bipolar Disorder: An Evidence-Based Guide to Manic Depression, Springer, New York, NY, USA, 2014.
5. C. F. Baldassano, A. Hosey, and J. Coello, "Bipolar depression: an evidence-based approach, " Current Psychiatry Reports, vol. 13, no. 6, pp. 483-487, 2011.
6. J. Zohar, S. Stahl, H.-J. Moller et al., "A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature, " European Neuropsychopharmacology, vol. 25, no. 12, pp. 2318-2325, 2015.
7. B. Stubbs, D. Vancampfort, M. Solmi, N. Veronese, and M. Fornaro, "How common is bipolar disorder in general primary care attendees? A systematic review and meta-analysis investigating prevalence determined according to structured clinical assessments, " Australian and New Zealand Journal of Psychiatry, vol. 50, no. 7, pp. 631-639, 2016.
8. K. N. Fountoulakis, X. Gonda, E. Vieta, and Z. Rihmer, "Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?" Annals of General Psychiatry, vol. 10, article 8, 2011.
9. J. K. Rybakowski, "Bipolarity and inadequate response to antidepressant drugs: clinical and psychopharmacological perspective, " Journal of Affective Disorders, vol. 136, no. 1-2, pp. e13-e19, 2012.
10. M. Fornaro, M. Martino, C. De Pasquale, and D. Moussaoui, "The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states?" Expert Opinion on Pharmacotherapy, vol. 13, no. 14, pp. 2037-2051, 2012.
11. I. Pacchiarotti, D. J. Bond, R. J. Baldessarini et al., "The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders, "TheAmerican Journal of Psychiatry, vol. 170, no. 11, pp. 1249-1262, 2013.
12. M. Sagud, A. Mihaljevic-Peles, D. Begic et al., "Antipsychotics as antidepressants: what is the mechanism?" Psychiatria Danubina, vol. 23, no. 3, pp. 302-307, 2011.
13. B. M. Wright, E. H. Eiland, and R. Lorenz, "Augmentation with atypical antipsychotics for depression: a review of evidencebased support from the medical literature, " Pharmacotherapy, vol. 33, no. 3, pp. 344-359, 2013.
14. L. Bjørklund, H. T. Horsdal, O. Mors, S. D. Østergaard, and C. Gasse, "Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study, " Acta Neuropsychiatrica, vol. 28, no. 2, pp. 75-84, 2016.
15. S. Dodd, B. S. Fernandes, and O. M. Dean, "Future directions for pharmacotherapies for treatment-resistant bipolar disorder, " Current Neuropharmacology, vol. 13, no. 5, pp. 656-662, 2015.
16. R. M. Post, "Treatment of bipolar depression: evolving recommendations, " Psychiatric Clinics of North America, vol. 39, no. 1, pp. 11-33, 2016.
17. M. Fornaro, D. De Berardis, A. S. Koshy et al., "Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review, " Neuropsychiatric Disease and Treatment, vol. 12, pp. 719-735, 2016.
18. M. Fornaro, B. Stubbs, D. De Berardis et al., "Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials, " International Journal of Molecular Sciences, vol. 17, no. 2, article 241, 2016.
19. A. Shah, P. Yadav, M. Chaudhari, J. Rai, andN. Kantharia, "Bipolar disorder: a review of current U. S. Food and Drug Administration approved pharmacotherapy, " International Journal of Basic and Clinical Pharmacology, pp. 623-631, 2015.
20. R. S. McIntyre, D. S. Cha, R. D. Kim, andR. B. Mansur, "Areview of FDA-approved treatment options in bipolar depression, " CNS Spectrums, vol. 18, supplement 1, pp. 4-21, 2013.
21. R. S. McIntyre, D. S. Cha, R. D. Kim, andR. B. Mansur, "Areview of FDA-approved treatment options in bipolar depression, " CNS Spectrums, vol. 18, supplement 1, pp. 1-21, 2013.
22. R. Bawa and J. R. Scarff, "Lurasidone: a new treatment option for bipolar depression-a review, " Innovations in Clinical Neuroscience, vol. 12, no. 1-2, pp. 21-23, 2015.
23. A. Loebel, J. Cucchiaro, R. Silva et al., "Lurasidonemonotherapy in the treatment of bipolar I depression: a randomized, doubleblind, placebo-controlled study, " American Journal of Psychiatry, vol. 171, no. 2, pp. 160-168, 2014.
24. A. Loebel, J. Cucchiaro, R. Silva et al., "Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study, " American Journal of Psychiatry, vol. 171, no. 2, pp. 169-177, 2014.
25. T. Suppes, H. Kroger, A. Pikalov, and A. Loebel, "Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts, " Journal of Psychiatric Research, vol. 78, pp. 86-93, 2016.
26. A. Dols, D. Rhebergen, A. Beekman, R. Kupka, M. Sajatovic, and M. L. Stek, "Psychiatric and medical comorbidities: results from a bipolar elderly cohort study, " American Journal of Geriatric Psychiatry, vol. 22, no. 11, pp. 1066-1074, 2014.
27. T. Ketter, K. Sarma, and R. Silva, "Lurasidone in bipolar I depression: a 24-week, open-label extension study [abstract no. 17 plus poster], " in Proceedings of the Annual Meeting of the American Society of Clinical Psychopharmacology, Hollywood, Fla, USA, 2014.
28. T. A. Ketter, K. Sarma, R. Silva, H. Kroger, J. Cucchiaro, and A. Loebel, "Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study, " Depression and Anxiety, vol. 33, no. 5, pp. 424-434, 2016.
29. C. B. Schaffer, L. C. Schaffer, T. E. Nordahl, N. M. Stark, and C. E. Gohring, "An open trial of lurasidone as an acute and maintenance adjunctive treatment for outpatients with treatment-resistant bipolar disorder, " Journal of Clinical Psychopharmacology, vol. 36, no. 1, pp. 88-89, 2016.
30. I. R. McGrane and M. Stuhec, "Comment on an open trial of lurasidone as an acute and maintenance adjunctive treatment for outpatients with treatment-resistant bipolar disorder, " Journal of Clinical Psychopharmacology, vol. 36, no. 5, pp. 520-521, 2016.
31. L. Citrome, T. A. Ketter, J. Cucchiaro, and A. Loebel, "Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed, " Journal of Affective Disorders, vol. 155, no. 1, pp. 20-27, 2014.
32. L. Citrome, "Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it, " Journal of Clinical Psychiatry, vol. 72, no. 3, pp. 412-413, 2011.
33. L. Alphs, J. Berwaerts, and I. Turkoz, "Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment response, " European Neuropsychopharmacology, vol. 23, no. 11, pp. 1597-1599, 2013.
34. R. Ganann, D. Ciliska, and H. Thomas, "Expediting systematic reviews: methods and implications of rapid reviews, " Implementation Science, vol. 5, no. 1, article 56, 2010.
35. H. Bastian, P. Glasziou, and I. Chalmers, "Seventy-five trials and eleven systematic reviews a day: how will we ever keep up?" PLoS Medicine, vol. 7, no. 9, Article ID e1000326, 2010.
36. D. Moher, J. Tetzlaff, A. C. Tricco, M. Sampson, and D. G. Altman, "Epidemiology and reporting characteristics of systematic reviews, " PLoS Medicine, vol. 4, no. 3, article e78, 2007.
37. T. D. Pigott, Advances inMeta-Analysis, Statistics for Social and Behavioral Sciences, Springer, New York, NY, USA, 2012.
38. R. M. Turner, S. M. Bird, and J. P. T. Higgins, "The impact of study size on meta-analyses: examination of underpowered studies in cochrane reviews, " PLoS ONE, vol. 8, no. 3, Article ID e59202, 2013.
39. V. Smith, D. Devane, C. M. Begley, and M. Clarke, "Methodology in conducting a systematic review of systematic reviews of healthcare interventions, " BMC Medical Research Methodology, vol. 11, article 15, 2011.
40. M. Tsagris and K. C. Fragkos, "Umbrella reviews, overviews of reviews, and meta-epidemiologic studies: similarities and differences, " in Umbrella Reviews, pp. 43-54, Springer International Publishing, Cham, Switzerland, 2016.
41. D. Moher, L. Shamseer, M. Clarke et al., "Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement, " Systematic Reviews, vol. 4, no. 1, p. 1, 2015.
42. B. J. Shea, J. M. Grimshaw, G. A. Wells et al., "Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews, " BMC Medical Research Methodology, vol. 7, no. 1, article 10, 2007.
43. B. J. Shea, C. Hamel, G. A. Wells et al., "AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews, " Journal of Clinical Epidemiology, vol. 62, no. 10, pp. 1013-1020, 2009.
44. J. Kung, F. Chiappelli, O. O. Cajulis et al., "From systematic reviews to clinical recommendations for evidence-based health care: validation of revised assessment of multiple systematic reviews (R-AMSTAR) for grading of clinical relevance, " The Open Dentistry Journal, vol. 4, no. 1, 2010.
45. K. Hemming, T. Pinkney, K. Futaba, M. Pennant, D. G. Morton, and R. J. Lilford, "A systematic review of systematic reviews and panoramic meta-analysis: staples versus sutures for surgical procedures, " PLoS ONE, vol. 8, no. 10, Article IDe75132, 2013.
46. M. De Hert, W. Yu, J. Detraux, K. Sweers, R. Van Winkel, and C. U. Correll, "Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder, " CNS Drugs, vol. 26, no. 9, pp. 733-759, 2012.
47. F. I. Tarazi and S. M. Stahl, "Iloperidone, asenapine and lurasidone: a primer on their current status, " Expert Opinion on Pharmacotherapy, vol. 13, no. 13, pp. 1911-1922, 2012.
48. K. Gao, C. Yuan, R. Wu et al., "Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat, " Neuroscience Bulletin, vol. 31, no. 5, pp. 572-588, 2015.
49. M. Sanford and S. Dhillon, "Lurasidone: a review of its use in adult patients with bipolar I depression, " CNS Drugs, vol. 29, no. 3, pp. 253-263, 2015.
50. R. R. Jaeschke, M. Sowa-Kúcma, P. Pánczyszyn-Trzewik, P. Misztak, K. Styczén, andW. Datka, "Lurasidone: the 2016 update on the pharmacology, efficacy and safety profile, " Pharmacological Reports, vol. 68, no. 4, pp. 748-755, 2016.
51. Y. S. Woo, H. R. Wang, and W.-M. Bahk, "Lurasidone as a potential therapy for bipolar disorder, " Neuropsychiatric Disease and Treatment, vol. 9, pp. 1521-1529, 2013.
52. L. J. Findlay, P. El-Mallakh, and R. S. El-Mallakh, "Management of bipolar I depression: clinical utility of lurasidone, " Therapeutics and Clinical Risk Management, vol. 11, pp. 75-81, 2015.
53. J. Angst, "The course of affective disorders, " Archiv für Psychiatrie und Nervenkrankheiten, vol. 226, no. 1, pp. 65-73, 1978.
54. J. P. T. Higgins, D. G. Altman, P. C. Gøtzsche et al., "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, " British Medical Journal, vol. 343, no. 7829, Article ID d5928, 2011.
55. D. Pieper, R. B. Buechter, L. Li, B. Prediger, and M. Eikermann, "Systematic review found AMSTAR, but not R(evised)-AMSTAR, to have good measurement properties, " Journal of Clinical Epidemiology, vol. 68, no. 5, pp. 574-583, 2015.
56. C. M. Faggion, "Critical appraisal of AMSTAR: challenges, limitations, and potential solutions from the perspective of an assessor, " BMC Medical Research Methodology, vol. 15, no. 1, article 63, 2015.
57. I. Popovich, B. Windsor, V. Jordan, M. Showell, B. Shea, and C. M. Farquhar, "Methodological quality of systematic reviews in subfertility: a comparison of two different approaches, " PLoS ONE, vol. 7, no. 12, Article IDe50403, 2012.
58. X. Qi, M. Yang, W. Ren et al., "Find duplicates among the PubMed, EMBASE, and cochrane library databases in systematic review, " PLoS ONE, vol. 8, no. 8, Article ID e71838, 2013.
59. A. Loebel, J. Xu, J. Hsu, J. Cucchiaro, and A. Pikalov, "The development of lurasidone for bipolar depression, " Annals of the New York Academy of Sciences, vol. 1358, no. 1, pp. 95-104, 2015.
60. L. Citrome, "A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach, " CNS Drugs, vol. 27, no. 11, pp. 879-911, 2013.
61. K. N. Fountoulakis, M. Gazouli, J. Kelsoe, and H. Akiskal, "The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder, " European Neuropsychopharmacology, vol. 25, no. 3, pp. 335-342, 2015.
62. W. M. Greenberg and L. Citrome, "Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a secondgeneration antipsychotic: a systematic review of the published literature, " Clinical Pharmacokinetics, vol. 56, no. 5, pp. 493-503, 2017.
63. R. S. McIntyre, D. S. Cha, M. Alsuwaidan, D. McIntosh, A. M. Powell, and J. M. Jerrell, "A review of published evidence reporting on the efficacy and pharmacology of lurasidone, " Expert Opinion on Pharmacotherapy, vol. 13, no. 11, pp. 1653-1659, 2012.
64. L. Orsolini, C. Tomasetti, A. Valchera et al., "An update of safety of clinically used atypical antipsychotics, " Expert Opinion on Drug Safety, vol. 15, no. 10, pp. 1329-1347, 2016.
65. J. M. Meyer, A. D. Loebel, and E. Schweizer, "Lurasidone: a new drug in development for schizophrenia, " Expert Opinion on Investigational Drugs, vol. 18, no. 11, pp. 1715-1726, 2009.
66. R. Franklin, S. Zorowitz, A. K. Corse, A. S. Widge, and T. Deckersbach, "Lurasidone for the treatment of bipolar depression: an evidence-based review, " Neuropsychiatric Disease and Treatment, vol. 11, pp. 2143-2152, 2015.
67. K. Rajagopalan, E. D. Bacci, K. W. Wyrwich, A. Pikalov, and A. Loebel, "Thedirect and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results froma randomized placebo-controlled trial, " International Journal of Bipolar Disorders, vol. 4, no. 1, p. 1, 2016.
68. Y.-Y. Chiu, L. Ereshefsky, S. H. Preskorn, N. Poola, and A. Loebel, "Lurasidone drug-drug interaction studies: a comprehensive review, " DrugMetabolismandDrug Interactions, vol. 29, no. 3, pp. 191-202, 2014.
69. W. K. Kennedy, M. W. Jann, and E. C. Kutscher, "Clinically significant drug interactions with atypical antipsychotics, " CNS Drugs, vol. 27, no. 12, pp. 1021-1048, 2013.
70. J. De Leon, V. Santoro, C. D'Arrigo, and E. Spina, "Interactions between antiepileptics and second-generation antipsychotics, " Expert Opinion on Drug Metabolism and Toxicology, vol. 8, no. 3, pp. 311-334, 2012.
71. L. Fala, "Latuda (Lurasidone HCl) Receives 2 New Indications for Use in Bipolar Depression as Monotherapy and as Adjunctive Therapy with Lithium or Valproate, " American Health & Drug Benefits.
72. "Sunivon-. Latuda- (lurasidoneHCl) Prescribing Information, " 2016, https://www. google. it/url?sa=t&rct=j&q=&esrc=s& source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwjc4oCE-3e7PAhVGshQKHXiQBwQQFggoMAA&url=http%3A%2F% 2Fwww. latuda. com%2FLatudaPrescribingInformation. pdf& usg=AFQjCNH01TNyYsBUFNHXmkeYUltV0h9-mA.
73. A. Loebel and L. Citrome, "Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression, " Psychiatrist, vol. 39, no. 5, pp. 237-241, 2015.
74. T. Horisawa, T. Ishibashi, H. Nishikawa et al., "The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone, " Behavioural Brain Research, vol. 220, no. 1, pp. 83-90, 2011.
75. T. Ishibashi, T. Horisawa, K. Tokuda et al., "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity, " Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 1, pp. 171-181, 2010.
76. K. N. Fountoulakis, J. R. Kelsoe, and H. Akiskal, "Receptor targets for antidepressant therapy in bipolar disorder: an overview, " Journal of Affective Disorders, vol. 138, no. 3, pp. 222-238, 2012.
77. J. K. Zubieta and N. E. Alessi, "Is there a role of serotonin in the disruptive behavior disorders? A literature review, " Journal of Child and Adolescent Psychopharmacology, vol. 3, no. 1, pp. 11-35, 1993.
78. L. N. Yatham, J. M. Goldstein, E. Vieta et al., "Atypical antipsychotics in bipolar depression: potential mechanisms of action, " Journal of Clinical Psychiatry, vol. 66, supplement 5, pp. 40-48, 2005.
79. P. Blier and N. M. Ward, "Is there a role for 5-HT1A agonists in the treatment of depression?" Biological Psychiatry, vol. 53, no. 3, pp. 193-203, 2003.
80. E. Brugue and E. Vieta, "Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications, " Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 1, pp. 275-282, 2007.
81. L. N. Cates, A. J. Roberts, S. Huitron-Resendiz, and P. B. Hedlund, "Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype, " Neuropharmacology, vol. 70, pp. 211-217, 2013.
82. M. Huang, M. Horiguchi, A. R. Felix, and H. Y. Meltzer, "5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux, " NeuroReport, vol. 23, no. 7, pp. 436-440, 2012.
83. O. Mnie-Filali, L. Lambas-Señas, H. Scarna, and N. Haddjeri, "Therapeutic potential of 5-HT7 receptors in mood disorders, " Current Drug Targets, vol. 10, no. 11, pp. 1109-1117, 2009.
84. H. Y. Meltzer, "The role of serotonin in antipsychotic drug action, " Neuropsychopharmacology, vol. 21, no. 2, pp. 106S-115S, 1999.
85. R. J. Roberts, K. K. Lohano, and R. S. El-Mallakh, "Antipsychotics as antidepressants, " Asia-Pacific Psychiatry, vol. 8, no. 3, pp. 179-188, 2015.
86. D. K. Shayegan and S. M. Stahl, "Atypical antipsychotics: matching receptor profile to individual patient's clinical profile, " CNS Spectrums, vol. 9, no. 10, pp. 6-14, 2004.
87. N. A. Keks, J. Hope, andD. Castle, "Lurasidone: anantipsychotic with antidepressant effects in bipolar depression?" Australasian Psychiatry, vol. 24, no. 3, pp. 289-291, 2016.
88. F. Fang, H. Sun, Z. Wang, M. Ren, J. R. Calabrese, and K. Gao, "Antipsychotic drug-induced somnolence: incidence, mechanisms, and management, " CNS Drugs, vol. 30, no. 9, pp. 845-867, 2016.
89. J. De Fruyt, E. Deschepper, K. Audenaert et al., "Second generation antipsychotics in the treatment of bipolar depression: a systematic review andmeta-analysis, " Journal of Psychopharmacology, vol. 26, no. 5, pp. 603-617, 2012.
90. L. Citrome, A. Pikalov, M. Tocco et al., Sunovion Pharmaceuticals Europe Ltd. to Present New Data on LATUDA-? (lurasidone) at the 23rd European Congress of Psychiatry.
91. M. Sajatovic, D. Ng-Mak, C. T. Solem, F. Lin, K. Rajagopalan, and A. Loebel, "Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis, " Therapeutic Advances in Psychopharmacology, vol. 6, no. 6, pp. 355-368, 2016.
92. M. G. Carta, M. F. Moro, A. E. Nardi, and J. R. Calabrese, "Potential use of lurasidone for the treatment of bipolar psychosis, " Expert Opinion on Investigational Drugs, vol. 24, no. 4, pp. 575-584, 2015.
93. A. Loebel, C. Siu, K. Rajagopalan, A. Pikalov, J. Cucchiaro, and T. A. Ketter, "Recovery in bipolar depression: post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study, " Journal of Affective Disorders, vol. 186, pp. 376-382, 2015.
94. R. S. McIntyre, J. Cucchiaro, A. Pikalov, H. Kroger, and A. Loebel, "Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial, " The Journal of Clinical Psychiatry, vol. 76, no. 4, pp. 398-405, 2015.
95. J. Lataster, J. Van Os, L. De Haan et al., "Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study, " Journal of Clinical Psychiatry, vol. 72, no. 10, pp. 1397-1404, 2011.
96. A. Nierenberg, J. Tsai, Y. Mao, A. Pikalov, T. Suppes, and A. Loebel, "Efficacy of lurasidone in major depression with mixed features: pattern of improvement in depressive and manic symptoms, " European Psychiatry, vol. 33, p. S423, 2016.
97. T. Suppes, R. Silva, J. Cucchiaro et al., "Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study, " American Journal of Psychiatry, vol. 173, no. 4, pp. 400-407, 2016.
98. J. Hu, R. Mansur, and R. S. McIntyre, "Mixed specifier for bipolarmania and depression: highlights ofDSM-5 changes and implications for diagnosis and treatment in primary care, " The Primary Care Companion for CNS Disorders, vol. 16, no. 2, 2014.
99. M. Fornaro, D. De Berardis, F. Iasevoli et al., "Corrigendum to 'Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and "therapeutic sensation seeking" in response towards subjective intolerance to pain' [J. Affect. Disord. 151 (2) (November 2013), 596-604], " Journal of Affective Disorders, vol. 170, p. 22, 2015.
100. M. Fornaro, D. De Berardis, F. Iasevoli et al., "Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: relationship with cyclothymic temperament and 'therapeutic sensation seeking' in response towards subjective intolerance to pain, " Journal of Affective Disorders, vol. 151, no. 2, pp. 596-604, 2013.
101. L. N. Yatham, S. Mackala, J. Basivireddy et al., "Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study, " The Lancet Psychiatry, vol. 4, no. 3, pp. 208-217, 2017.
102. K. E. Burdick, T. A. Ketter, J. F. Goldberg, and J. R. Calabrese, "Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design, " Journal of Clinical Psychiatry, vol. 76, no. 3, pp. e342-e350, 2015.
103. C. T. Sudhir Kumar and S. Frangou, "Clinical implications of cognitive function in bipolar disorder, " Therapeutic Advances in Chronic Disease, vol. 1, no. 3, pp. 85-93, 2010.
104. M. A. Frye, M. L. Prieto, W. V. Bobo et al., "Current landscape, unmet needs, and future directions for treatment of bipolar depression, " Journal of AffectiveDisorders, vol. 169, no. 1, pp. S17-S23, 2014.
105. A. Pikalov, J. Tsai, Y. Mao, R. Silva, J. Cucchiaro, and A. Loebel, "Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment, " International Journal of Bipolar Disorders, vol. 5, no. 1, article 9, 2017.
106. American Psychiatric Association Publishing, Diagnostic and Statistical Manual of Mental Disorders (DSM-5), American Psychiatric Association Publishing, 2013.
107. G. M. Goodwin, P. M. Haddad, I. N. Ferrier et al., "Evidencebased guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology, " Journal of Psychopharmacology, vol. 30, no. 6, pp. 495-553, 2016.